A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

NCT03036150 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4304

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease

Interventions

DRUG: Dapagliflozin
DRUG: Placebo

Sponsor

AstraZeneca